1. Introduction {#sec1}
===============

Central serous chorioretinopathy (CSC) is a maculopathy typically presenting with relative central scotoma, metamorphopsia, and decreased central vision; it mainly affects middle-aged men \[[@B1], [@B2]\]. CSC is one of the most common nonsurgical retinopathies \[[@B2]\]. The typical finding of CSC is serous neurosensory retinal detachment over the posterior pole due to impaired activity of the retinal pigment epithelium and changes of choroidal hemodynamics \[[@B3], [@B4]\]. CSC is frequently self-limited with good recovering visual outcome \[[@B5]\]. However, CSC recurrence may result in considerable and irreversible visual acuity loss due to extensive retinal pigment epithelium damage \[[@B6]\].

The etiology of CSC remains unclear. The disease has been associated with psychological stress \[[@B7]--[@B9]\]. Studies also have revealed that endogenous hypercortisolism, psychopharmacologic medication, glucocorticoid medication, hypertension, elevated circulating cortisol and catecholamines, and peptic ulcer are risk factors for CSC \[[@B10]--[@B16]\]. Sleep disturbance is a common complaint and source of distress in community surveys of self-reported health problems \[[@B17]--[@B19]\]. An early sign of psychiatric disorder was probably sleep disturbance. Furthermore, psychological stress may be caused by sleep disturbance \[[@B20]\]. Leveque et al. \[[@B21]\] found CSC patients may be more likely than others to have sleep apnea. Kloos et al. \[[@B22]\] reported that sleep apnea may be a risk factor for the development of CSC. Bousquet et al. \[[@B8]\], Liu et al. \[[@B15]\], and Eom et al. \[[@B23]\] also reported that sleep disturbance was associated with CSC. Nevertheless, some studies revealed that patients with CSC were not statistically significant related to those with sleep apnea \[[@B24], [@B25]\]. The controversial results indicated that more and detailed studies are required to understand the association between sleep disturbance with CSC \[[@B15]\]. Since sleep apnea is generally with organic origin, in the present study, we intended to understand whether sleep disturbance with nonorganic origin exhibits higher risk of CSC. We analyzed and compared the incidences of CSC in the NOSD group and in the control group without NOSD using the national population-based dataset from Taiwan National Health Insurance (TNHI).

2. Methods {#sec2}
==========

2.1. Database {#sec2.1}
-------------

The Taiwan Bureau of National Health Insurance (TBNHI) integrated all 13 public health insurance systems since 1995 into a large insurance program. Enrollment in this program is mandatory for people in Taiwan, and the covered rate is over 99% Taiwanese. TBNHI entrusted National Health Research Institutes to construct and maintain the National Health Insurance Research Database (NHIRD) from this program. The Longitudinal Health Insurance Database (LHID) was a part of NHIRDs, and it contained one million beneficiaries selected randomly from the year 2000 Registry of Beneficiaries. This database included all inpatient and outpatient medical claims for each beneficiary from the start of 1996 to the end of 2011. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used to identify the disease. The patient\'s identification code in the NHIRDs was recorded by TBNHI based on the Personal Information Protection Act. All researchers signed the written agreement for no intention of attempting to obtain patients\' privacy. This study was also approved by the Research Ethics Committee in China Medical University Hospital, Taiwan.

2.2. Study Population, Outcome, and Comorbidity {#sec2.2}
-----------------------------------------------

We collected 53,862 patients with NOSD diagnosis (ICD-9-CM 307.4 and 780.5) and age at 20--50 years between 2000 and 2005 from LHID as the NOSD cohort. The date for NOSD diagnosis was defined as the index date. In the NOSD group, NOSD patients with CSC (ICD-9-CM 362.41) were excluded before the index date (*n* = 119). Controls were selected randomly from people in the LHID without sleep disurbance and CSC history as the control group, with frequency-matched criteria including age (5-year stratum), sex, and index-year at a ratio of 4 : 1.

All study subjects were followed from the index date to the date when CSC developed. All selected study subjects were followed to the date of withdrawal from this program or the end of 2011. The follow-up time, in person-years, was counted for each study subject. Potential comorbidity we considered included hypertension (ICD-9-CM 401--405), hyperlipidemia (ICD-9-CM 272), diabetes (ICD-9-CM 250), depression (ICD-9-CM 296.2, 296.3, 300.1, and 311), anxiety (ICD-9-CM 300.0, 300.2, 300.3, 308.3, and 309.81), alcohol-related disease (ICD-9-CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, A215, and V11.3), smoking-related disease (ICD-9-CM 305.1, 430--438, 410--414, and 490--496), and obesity (ICD-9-CM). All comorbidities were defined before the index date. Patients who had received steroid treatment within 1 year before CSC development were defined as steroid users.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The difference between the two groups, demographics, and comorbidity was compared by the *χ*^2^ test. The CSC incidences were measured in the NOSD and control groups. The hazard ratio (HR) and 95% confidence intervals (CIs) for CSC and CSC-associated risk factors were estimated in crude and adjusted Cox proportional hazard regression models. An adjusted model controlled for the variables that had significant differences in the crude model. Age-, sex-, comorbidity-, and steroid use-specific risks for CSC in the NOSD group were compared with those in the control group with the Cox model. Furthermore, we estimated the association between CSC and the severity of NOSD. The severity was classified as mild and serious according to NOSD patients who received sleeping pill treatment within 1 year before the CSC occurred. Kaplan--Meier analysis was used to measure the cumulative incidence for CSC during the study period in both groups, and the log-rank test was used to test the difference in incidences between both groups. SAS 9.4 statistical software (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses in this study. The significant level was set at *P* \< 0.05, 2-tailed test.

3. Results {#sec3}
==========

We all collected 268,715 study subjects in this retrospective cohort study, 53,743 NOSD patients and 214,972 controls. In the NOSD group, there were more women than men (64.7% vs. 35.3%). The mean age was 36.8 ± 8.40 years. Compared with the controls, NOSD patients were more likely to have comorbidities, including hypertension (10.3% vs. 5.59%; 95%, *P* \< 0.0001), diabetes (3.48% vs. 2.33%; 95%, *P* \< 0.0001), hyperlipidemia (8.82% vs. 4.96%; 95%, *P* \< 0.0001), depression (5.60% vs. 1.09%; 95%, *P* \< 0.0001), anxiety (10.9% vs. 2.44%; 95%, *P* \< 0.0001), alcohol-related disease (2.93% vs. 1.12%; 95%, *P* \< 0.0001), smoking-related disease (25.4% vs. 13.9%; 95%, *P* \< 0.0001), and obesity (1.22% vs. 0.77%; 95%, *P* \< 0.0001). NOSD patients received steroid treatment more often than the control group (37.2% vs. 26.8%; 95%, *P* \< 0.0001; [Table 1](#tab1){ref-type="table"}).

During a mean 7.36 ± 2.88 years of follow-up, 281 and 144 patients had CSC in the control and NOSD groups, respectively, with incidences of 1.86 and 3.10 per 10,000 person-years, respectively ([Table 2](#tab2){ref-type="table"}). After 12 years of follow-up, the cumulative incidence for CSC in the NOSD cohort was approximately 0.09% higher than the control cohort (0.29% vs. 0.20%, log rank test *P* \< 0.0001; [Figure 1](#fig1){ref-type="fig"}).

NOSD patients had a 1.71-and 1.65-fold risk for CSC compared with non-NOSD controls in the crude and adjusted Cox models (95% CI, 1.40--2.09 and 1.34--2.02, respectively). In the multivariable Cox model, men and steroid usage had a higher risk for CSC than women and nonsteroid usage (HR, 2.51 and 1.33; 95% CI, 2.07--3.05 and 1.08--1.63, respectively; [Table 2](#tab2){ref-type="table"}).

[Table 3](#tab3){ref-type="table"} presents the risk for CSC in the NOSD compared with the non-NOSD control group stratified by age, sex, comorbidity, and steroid use. NOSD women had a 1.72-fold higher risk than control women, and NOSD men also had a 1.59-fold higher risk than control men in the multivariable Cox model. No matter at what age, NOSD patients had a significantly more than 1.44-fold risk for CSC than controls. NOSD patients with or without any other comorbidity also had a higher risk of CSC. Furthermore, NOSD patients without steroid treatment had a significantly higher risk of developing CSC.

The association between CSC and NOSD severity is shown in [Table 4](#tab4){ref-type="table"}. Of the NOSD patients, 61% (32,839/53,743) received sleeping pill treatment and were classified into the serious NOSD group. The CSC incidence increased with NOSD severity from 1.86 to 3.01 and 3.16 per 10,000 person-years in the controls, mild-NOSD, and serious-NOSD groups, respectively (*P* for trend \< 0.0001). Compared with the control group, serious-NOSD patients exhibited 1.72-fold (95% CI, 1.35--2.20) increased risk of having CSC and a 1.55-fold risk (95% CI, 1.16--2.07) in the mild-NOSD patients.

4. Discussion {#sec4}
=============

To our knowledge, this study is the first to assess the relationship of NOSD inducing CSC, with a large-scale nationwide representative database (*n* = 268,715) and long-term follow-up study design. NOSD patients had a higher risk for CSC, no matter in which sex, age group, or comorbidity condition.

NOSD patients had higher alcohol-related and smoking-related diseases. However, alcohol and smoking were not significant risk factors for CSC in our study. A recent study also had shown that tobacco was not involved in the development of CSC \[[@B15]\]. NOSD was related to CSC, independent of alcohol-related and smoking-related diseases. The severity of NOSD was defined by the use of sleeping pills. We found a higher incidence of CSC in patients with serious NOSD than mild NOSD patients, which suggested the importance of NOSD in the pathogenesis of CSC. The data also suggested that taking sleeping pills may increase the incidence of CSC. We did not analyze the effect of each different sleeping pills on the incidence of CSC in this study. We are now evaluating the outcomes of each different sleeping pills on the incidence of CSC.

It has been noted that corticosteroids were associated with the initiation, exacerbation or prolongation of central serous chorioretinopathy \[[@B11]\]. Another report indicated that not only the systematic but also inhalant or nasal use of steroid could increase the risk of CSC \[[@B15]\]. Nevertheless, NOSD patients had a higher CSC risk regardless of steroid use in our study, especially among those who did not undergo steroid treatment showing significant difference. In this study, we did not discuss the dosage and duration of the steroids, which may cause the discrepancy between our results and the reported data.

The significant points of our study are that the source of patients is based on a nationwide population-based database, which covers over 99% of the population in Taiwan and decreases the selection bias. Moreover, the longitudinal study was used to assess CSC risk-related NOSD.

This study has some potential limitations. First, diagnoses of CSC from health insurance database have been often challenged. However, the best effort had been made in this large population study based on NHIRD as in many reports in the literature \[[@B16], [@B25]--[@B28]\]. Second, personal information, such as psychological stress, alcohol/cigarette consumption, and body mass index (BMI), was not available from the administrative database, and this somehow may have compromised our results. However, after considering alcohol- and smoking-related diseases, the results in our study were not significant. Bordie et al. \[[@B24]\] proposed that BMI might bias the relationship between sleep apnea and CSC. Thus, we considered obesity as another comorbidity, and the result in our study was also not significant. Third, several asymptomatic or mildly symptomatic CSC patients may not have visited an ophthalmologic clinic, which may have led to underestimation of the risk with nondifferential misclassification. Moreover, there is not standardized diagnosis tool available on NOSD for each different physician. Some patients may actually suffer from different sleep disorders.

In our multivariable Cox model, men had a higher risk for CSC than women (HR, 2.51; 95% CI, 2.07--3.05; [Table 2](#tab2){ref-type="table"}). This is consistent with a previous study showing CSC to be a male-predominant disease \[[@B1], [@B2], [@B26]\]. Sleep disturbance is a common health issue. Many sleep disorders, such as insomnia, hypersomnia, and sleep apnea, are included in sleep disturbance. Inadequate sleep is associated with cardiovascular disease \[[@B29]\]. CSC also was noted to be associated with an increased risk of stroke and coronary heart disease \[[@B27], [@B28]\]. Elevated catecholamine and cortisol levels were found in a sleep apnea population \[[@B30], [@B31]\]. Altered catecholamine levels and sympathetic activity often have been reported to accompany sleep disturbance \[[@B31], [@B32]\]. Sun et al. found that plasma concentrations of both catecholamines (epinephrine and norepinephrine) were significantly higher in active CSC than normal subjects, and then decreased to normal in the convalescent stage. They also found that plasma concentration of epinephrine was significantly correlated with macular edema. They proposed that prolonged stimulation of high catecholamine level might provoke focal RPE cells dysfunction, resulting in a breakdown of the outer blood-retinal barrier and then diffusion of fluids, which promoted CSC \[[@B33]\]. Those pathophysiological pathways might constitute a hypothetical connection between NOSD and CSC.

In conclusion, we demonstrated large-scale epidemiological evidence of a significantly increased risk for subsequent CSC development among an NOSD population. Decreased central vision or metamorphopsia in NOSD patients may need further macular examinations to exclude the possibility of CSC.
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![Cumulative incidence for central serous chorioretinopathy (CSC) in the no organic sleep disturbance (NOSD) and control cohorts. After 12 years of follow-up, the cumulative incidence for CSC in the NOSD cohort was approximately 0.09% higher than that in the control cohort (0.29% vs. 0.20%, log-rank test (*P* \< 0.0001)).](JOPH2020-1712503.001){#fig1}

###### 

Demographic characteristics between NOSD and comparsion cohort.

  -------------------------------------------------------------------------------------------------
  Characteristics            NOSD\               \%     Comparsions\         \%     *P* value^\$^
                             *N* = 53743 (*n*)          *N* = 214972 (*n*)          
  -------------------------- ------------------- ------ -------------------- ------ ---------------
  Sex                                                                               0.99

   Women                     34,774              64.7   139,096              64.7    

   Men                       18,969              35.3   75,876               35.3    

  Age (years)                                                                       0.99

   20--29                    12,479              23.2   49,916               23.2    

   30--39                    18,627              34.7   74,508               34.7    

   40--50                    22,637              42.1   90,548               42.1    

   Mean                      36.8                8.40   37.1                 8.25    

  Comorbidity                                                                        

   Hypertension              5548                10.3   12,026               5.59   \<0.0001

   Diabetes                  1870                3.48   5000                 2.33   \<0.0001

   Hyperlipidemia            4742                8.82   10,658               4.96   \<0.0001

   Depression                3010                5.60   2353                 1.09   \<0.0001

   Anxiety                   5876                10.9   5249                 2.44   \<0.0001

   Alcohol-related disease   1577                2.93   2407                 1.12   \<0.0001

   Smoking-related disease   13,645              25.4   29,896               13.9   \<0.0001

   Obesity                   654                 1.22   1646                 0.77   \<0.0001

  Steroid users              19,964              37.2   57,563               26.8   \<0.0001
  -------------------------------------------------------------------------------------------------

^\$^Chi-square test.NOSD: nonorganic sleep disturbance.

###### 

Incidence and risk for CSC and associated comorbidities.

                            Event no.   Person per years   Rate^§^   Crude HR^§^ (95% CI)       Adjusted HR^§^ (95% CI)
  ------------------------- ----------- ------------------ --------- -------------------------- --------------------------
  NOSD                                                                                           
   No                       281         1,512,968          1.86      1.00                       1.00
   Yes                      144         464,176            3.10      1.71 (1.40--2.09)^*∗∗∗*^   1.65 (1.34--2.02)^*∗∗∗*^
  Sex                                                                                            
   Women                    176         1,256,555          1.40      1.00                       1.00
   Men                      249         720,590            3.46      2.47 (2.04--3.00)^*∗∗∗*^   2.51 (2.07--3.05)^*∗∗∗*^
  Age (years)                                                                                    
   20--29                   86          461,051            1.87      1.00                       ---
   30--39                   155         689,607            2.25      1.21 (0.93--1.58)          ---
   40--50                   184         826,487            2.23      1.20 (0.93--1.55)          ---
  Comorbidity                                                                                    
  Hypertension                                                                                   
   No                       387         1,849,898          2.09      1.00                       1.00
   Yes                      38          127,246            2.99      1.44 (1.03--2.01)^*∗*^     1.08 (0.76--1.54)
  Diabetes                                                                                       
   No                       410         1,928,583          2.13      1.00                       ---
   Yes                      15          48,562             3.09      1.45 (0.87--2.43)          ---
  Hyperlipidemia                                                                                 
   No                       386         1,866,904          2.07      1.00                       1.00
   Yes                      39          110,241            3.54      1.72 (1.24--2.39)^*∗∗*^    1.34 (0.94--1.90)
  Depression                                                                                     
   No                       414         1,938,883          2.14      1.00                       ---
   Yes                      11          38,262             2.87      1.35 (0.74--2.46)          ---
  Anxiety                                                                                        
   No                       401         1,897,576          2.11      1.00                       ---
   Yes                      24          79,568             3.02      1.43 (0.95--2.16)          ---
  Alcohol-related disease                                                                        
   No                       416         1,950,593          2.13      1.00                       ---
   Yes                      9           26,552             3.39      1.57 (0.81--3.04)          ---
  Smoking-related disease                                                                        
   No                       349         1,664,185          2.10      1.00                       ---
   Yes                      76          312,959            2.43      1.16 (0.91--1.49)          ---
  Obesity                                                                                        
   No                       421         1961556            2.15      1.00                       ---
   Yes                      4           15589              2.57      1.18 (0.44--3.15)          ---
  Steroid usage                                                                                  
   No                       279         1,420,146          1.96      1.00                       1.00
   Yes                      146         556,999            2.62      1.34 (1.09--1.63)^*∗∗*^    1.33 (1.08--1.63)^*∗∗*^

^§^Per 10000 person-years. ^*∗*^*P* \< 0.05, ^*∗∗*^*P* \< 0.01, ^*∗∗∗*^*P* \< 0.001. CSC: central serous chorioretinopathy, NOSD: nonorganic sleep disturbance, HR: hazard ratio, CI: confidence interval.

###### 

Incidence and risk for CSC in NOSD compared with non-NOSD cohort stratified by age, sex, comorbidity, and steroid usage.

                     NOSD event no.   Person per years   Rate^§^   Control event no.   Person per years   Rate^§^   HR 95% (CI) crude          Adjusted
  ------------------ ---------------- ------------------ --------- ------------------- ------------------ --------- -------------------------- --------------------------
  Sex^1^                                                                                                                                        
   Women             64               303,885            2.11      112                 952,670            1.18      1.82 (1.34--2.48)^*∗∗∗*^   1.72 (1.26--2.35)^*∗∗∗*^
   Men               80               160,291            4.99      169                 560,300            3.02      1.69 (1.29--2.20)^*∗∗∗*^   1.59 (1.21--2.09)^*∗∗∗*^
  Age (years)^2^                                                                                                                                
   20--29            34               105,361            3.23      52                  355,690            1.46      2.24 (1.46--3.46)^*∗∗∗*^   2.26 (1.46--3.50)^*∗∗∗*^
   30--39            52               161,231            3.23      103                 528,375            1.95      1.69 (1.21--2.37)^*∗∗*^    1.62 (1.15--2.27)^*∗∗*^
   40--50            58               197,584            2.94      126                 628,903            2.00      1.50 (1.10--2.05)^*∗*^     1.44 (1.05--1.98)^*∗*^
  Comorbidity^3^                                                                                                                                
   Without any one   68               254048             2.68      214                 1190351            1.80      1.52 (1.15--1.99)^*∗∗*^    1.52 (1.15--2.00)^*∗∗*^
   With any one      76               210128             3.62      67                  322617             2.08      1.79 (1.28--2.48)^*∗∗∗*^   1.76 (1.26--2.44)^*∗∗∗*^
  Steroid usage^4^                                                                                                                              
   No                92               292,090            3.15      187                 1,128,056          1.66      1.94 (1.51--2.49)^*∗∗∗*^   1.90 (1.48--2.45)^*∗∗∗*^
   Yes               52               172,087            3.02      94                  384,912            2.44      1.26 (0.90--1.77)          1.28 (0.91--1.80)

^1^Adjusted for hyperlipidemia, hypertension, and steroid use. ^2^Adjusted for sex, hyperlipidemia, hypertension, and steroid use. ^3^Adjusted for sex and steroid use. ^4^Adjusted for sex, hyperlipidemia, and hypertension. ^§^Per 10000 person-years. ^*∗*^*P* \< 0.05, ^*∗∗*^*P* \< 0.01, ^*∗∗∗*^*P* \< 0.001. CSC: central serous chorioretinopathy, NOSD: nonorganic sleep disturbance, HR: hazard ratio, CI: confidence interval.

###### 

Incidence and risk for CSC among different NOSD severity.

                   *N*       Event no.   Person-years   Rate^§^    Crude HR (95% CI)          Adjusted HR (95% CI)
  ---------------- --------- ----------- -------------- ---------- -------------------------- --------------------------
  Controls         214,972   281         1,512,968      1.86       1.00                       1.00
  NOSD                                                                                         
   Mild            20,904    56          185,833        3.01       1.67 (1.25--2.22)^*∗∗∗*^   1.55 (1.16--2.07)^*∗∗*^
   Serious         32,839    88          278,343        3.16       1.73 (1.36--2.20)^*∗∗∗*^   1.72 (1.35--2.20)^*∗∗∗*^
   *P* for trend                                        \<0.0001   \<0.0001                   \<0.0001

^§^Per 10000 person-years. Adjusted for sex, hyperlipidemia, hypertension, and steroid use. ^*∗*^*P* \< 0.05, ^*∗∗*^*P* \< 0.01, ^*∗∗∗*^*P* \< 0.001. CSC: central serous chorioretinopathy, NOSD: nonorganic sleep disturbance, HR: hazard ratio, CI: confidence interval.
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